Muscarinic acetylcholine receptor: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(reformatted date to remove error tag)
(ß2 changd to ß<sub>2</sub>)
Line 1: Line 1:
'''Muscarinic acetylcholine receptors''', or mAChRs, are [[acetylcholine]] receptors that form G protein-receptor complexes in the cell membranes of certain [[neuron]]s and other [[cell]]s. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibers in the [[parasympathetic nervous system]].
'''Muscarinic acetylcholine receptors''', or mAChRs, are [[acetylcholine]] receptors that form G protein-receptor complexes in the cell membranes of certain [[neuron]]s and other [[cell]]s. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibers in the [[parasympathetic nervous system]].


In 2015, a large German study found 29% of [[ME/CFS]] patients had elevated autoantibodies to M3 and M4 muscarinic acetylcholine receptors, as well as ß2 [[adrenergic receptors]].<ref>{{Cite web|url=http://www.meaction.net/2015/09/26/antibodies-found-in-subset-of-cfs-patients/|title=Autoantibodies found in subset of CFS patients {{!}} #MEAction|website=www.meaction.net|language=en-US|access-date=2018-08-10}}</ref><ref>{{Cite journal|last=Loebel|first=Madlen|last2=Grabowski|first2=Patricia|last3=Heidecke|first3=Harald|last4=Bauer|first4=Sandra|last5=Hanitsch|first5=Leif G.|last6=Wittke|first6=Kirsten|last7=Meisel|first7=Christian|last8=Reinke|first8=Petra|last9=Volk|first9=Hans-Dieter|date=Feb 2016|title=Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome|url=https://www.ncbi.nlm.nih.gov/pubmed/26399744|journal=Brain, Behavior, and Immunity|volume=52|pages=32–39|doi=10.1016/j.bbi.2015.09.013|issn=1090-2139|pmid=26399744}}</ref>
In 2015, a large German study found 29% of [[ME/CFS]] patients had elevated autoantibodies to M3 and M4 muscarinic acetylcholine receptors, as well as ß<sub>2</sub> [[adrenergic receptors]].<ref>{{Cite web|url=http://www.meaction.net/2015/09/26/antibodies-found-in-subset-of-cfs-patients/|title=Autoantibodies found in subset of CFS patients {{!}} #MEAction|website=www.meaction.net|language=en-US|access-date=2018-08-10}}</ref><ref>{{Cite journal|last=Loebel|first=Madlen|last2=Grabowski|first2=Patricia|last3=Heidecke|first3=Harald|last4=Bauer|first4=Sandra|last5=Hanitsch|first5=Leif G.|last6=Wittke|first6=Kirsten|last7=Meisel|first7=Christian|last8=Reinke|first8=Petra|last9=Volk|first9=Hans-Dieter|date=Feb 2016|title=Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome|url=https://www.ncbi.nlm.nih.gov/pubmed/26399744|journal=Brain, Behavior, and Immunity|volume=52|pages=32–39|doi=10.1016/j.bbi.2015.09.013|issn=1090-2139|pmid=26399744}}</ref>


==See also==
==See also==

Revision as of 21:32, August 10, 2018

Muscarinic acetylcholine receptors, or mAChRs, are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certain neurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibers in the parasympathetic nervous system.

In 2015, a large German study found 29% of ME/CFS patients had elevated autoantibodies to M3 and M4 muscarinic acetylcholine receptors, as well as ß2 adrenergic receptors.[1][2]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. "Autoantibodies found in subset of CFS patients | #MEAction". www.meaction.net. Retrieved August 10, 2018.
  2. Loebel, Madlen; Grabowski, Patricia; Heidecke, Harald; Bauer, Sandra; Hanitsch, Leif G.; Wittke, Kirsten; Meisel, Christian; Reinke, Petra; Volk, Hans-Dieter (February 2016). "Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome". Brain, Behavior, and Immunity. 52: 32–39. doi:10.1016/j.bbi.2015.09.013. ISSN 1090-2139. PMID 26399744.